Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1978 May;61(5):1309-19.
doi: 10.1172/JCI109048.

Quantitative influence of antibody and complement coating of red cells on monocyte-mediated cell lysis

Quantitative influence of antibody and complement coating of red cells on monocyte-mediated cell lysis

R J Kurlander et al. J Clin Invest. 1978 May.

Abstract

Monocyte-mediated lysis in vitro of human red cells coated with measured amounts of immunoglobulin G (IgG) or complement were studied. 1,000-1,500 molecules of IgG anti-D are necessary to effect measurable lysis, and lysis increases linearly with increasing levels of antibody sensitization. 100 microgram/ml of IgG1 abolished lysis even at maximal levels of anti-D sensitization (15,000 molecules/cell). Two isoimmune IgG anti-A or anti-B antisera were 5 to 10-fold less efficient in promoting phagocytosis or lysis per molecule of IgG bound; however, because of the greater antigen density of A or B, more than 100,000 molecules IgG/cell could be bound, producing equivalent lysis to anti-D-coated cells. Although inhibition by IgG1 was similar at equivalent levels of sensitization with anti-A, anti-B, or anti-D at high levels of coating with anti-A or anti-B (not attainable with anti-D), lysis was not inhibited by IgG1. Cells coated with human complement components alone were not lysed by monocytes; however, complement coating augmented IgG-mediated lysis and reduced the quantity of anti-D necessary to produce lysis to less than 1,000 molecules/cell. After thorough degradation of C3b by serum to C3d, complement augmentation persisted.

PubMed Disclaimer

Similar articles

Cited by

References

    1. J Exp Med. 1975 May 1;141(5):1163-80 - PubMed
    1. J Clin Invest. 1971 Apr;50(4):734-43 - PubMed
    1. Blood. 1976 Dec;48(6):809-16 - PubMed
    1. Semin Hematol. 1976 Oct;13(4):267-75 - PubMed
    1. Semin Hematol. 1976 Oct;13(4):277-89 - PubMed

Publication types